★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Corteva, Inc. (CTVA) Moat Analysis
Corteva, Inc.
CTVA · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Corteva has two agricultural-input businesses: Seed and Crop Protection. Seed has the stronger moat through proprietary germplasm and trait IP, current premium mix, and monetization through out-licensing; farmers can nevertheless change brands annually and rival genetics remain strong. Crop Protection has a narrower, product-level IP advantage backed by a broad aggregate patent estate and current new-product demand, but generic entry and 2026 price declines demonstrate weak portfolio-wide pricing power. R&D spending, launch counts, productivity programs, distribution reach and cross-segment bundles were not treated as standalone moats without comparative evidence. Corteva is targeting October 1, 2026 for the Vylor Seed-business spin-off.
Primary segment
Seed
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
2 segments · 7 tags
Updated 2026-08-10
Segments
Seed
Commercial agricultural seeds and traits (corn, soybean, and other crops)
Revenue
71%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Crop Protection
Crop protection (herbicides, insecticides, fungicides, seed treatments, and biologicals)
Revenue
29%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
Moat Claims
Seed
Commercial agricultural seeds and traits (corn, soybean, and other crops)
Revenue share uses Q2 2026 segment net sales (Seed $4.532B of $6.379B). Operating profit share uses reported segment operating EBITDA (Seed $1.966B of $2.308B across the two segments). Source: Corteva Form 10-Q for quarter ended 2026-06-30: https://www.sec.gov/Archives/edgar/data/1755672/000175567226000025/ctva-20260630.htm
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Proprietary germplasm and trait IP support differentiated seed performance and licensing income; the advantage is portfolio-level rather than dependent on one patent.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Trait patent expirations and generic trait entry
- Regulatory restrictions on biotech traits or gene-editing
- Breakthrough competitor genetics/traits reduce differentiation
Leading indicators
- Out-licensing/royalty income trend
- Adoption rates of core trait platforms (e.g., Enlist system)
- Pipeline milestones and regulatory approvals for new traits
Counterarguments
- Large competitors also hold extensive trait IP; licensing can be reciprocal
- Farmers can switch seed brands annually if performance/price disappoints
Crop Protection
Crop protection (herbicides, insecticides, fungicides, seed treatments, and biologicals)
Revenue share uses Q2 2026 segment net sales (Crop Protection $1.847B of $6.379B). Operating profit share uses reported segment operating EBITDA (Crop Protection $342M of $2.308B across the two segments). Source: Corteva Form 10-Q for quarter ended 2026-06-30: https://www.sec.gov/Archives/edgar/data/1755672/000175567226000025/ctva-20260630.htm
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
A broad patent and trade-secret estate protects parts of the product portfolio, while current demand for new products shows commercial relevance; the advantage is product-specific and erodes after patent expiry.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry and generic competition
- Regulatory bans/restrictions on specific active ingredients
- Pest/weed resistance reduces product efficacy
Leading indicators
- Sales mix from newer products vs legacy portfolio
- Gross margin and price realization by region
- Regulatory outcomes and re-registration timelines
Counterarguments
- Crop protection markets often commoditize quickly as generics enter
- Competitors can match portfolios via acquisition or in-licensing
Evidence
substantially all of the company's branded soybean portfolio offers the Enlist E3® trait, in proprietary Corteva germplasm
Directly establishes that a major branded soybean portfolio combines a proprietary genetic base with a differentiated trait platform.
Enlist E3® technology has rapidly become the leading herbicide tolerance trait for soybeans in the United States.
Issuer-reported U.S. trait leadership is a focused adoption signal, not an estimate of Corteva share across the broader seed market.
The increase in pricing and mix was driven by demand for top technology and increased out-licensing income
Current-quarter commercial evidence ties premium mix and third-party licensing directly to the technology portfolio.
The settlement agreements support Corteva's product out-licensing growth in competitive corn, cotton and canola markets
Documents a current pathway for monetizing trait technology outside Corteva-branded seed, while the related settlement also illustrates IP-dependency risk.
the company owned about 5,900 U.S. patents and about 10,200 active patents outside of the U.S.
Quantifies the aggregate patent estate supporting both operating segments; it is not a Crop Protection-only patent count.
Showing 5 of 8 sources.
Risks & Indicators
Erosion risks
- Trait patent expirations and generic trait entry
- Regulatory restrictions on biotech traits or gene-editing
- Breakthrough competitor genetics/traits reduce differentiation
- Patent expiry and generic competition
- Regulatory bans/restrictions on specific active ingredients
- Pest/weed resistance reduces product efficacy
Leading indicators
- Out-licensing/royalty income trend
- Adoption rates of core trait platforms (e.g., Enlist system)
- Pipeline milestones and regulatory approvals for new traits
- Sales mix from newer products vs legacy portfolio
- Gross margin and price realization by region
- Regulatory outcomes and re-registration timelines
Research CTVA elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.